Skip to main content

Table 3 Summary of ORR and CRR comparisons between the TRANSCEND and ZUMA-1 studies

From: Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma

 

ZUMA-1 (axi-cel)

TRANSCEND (liso-cel)

Liso-cel versus axi-cel

N (%)

Response rate, %

N/ESS

Response rate, %

OR (95% CI)

P

ORR

 Naïve comparison

101

74.3

256

72.7

0.92 (0.54–1.55)

0.753

 Initial analysis

  

42.1

80.1

1.40 (0.56–3.49)

0.476

 Sensitivity analysis 1

  

150.3

71.2

0.85 (0.48–1.52)

0.591

 Sensitivity analysis 2

  

98.9

70.9

0.84 (0.45–1.58)

0.596

CRR

 Naïve comparison

101

54.5

256

53.1

0.95 (0.60–1.50)

0.815

 Initial analysis

  

39.6

59.2

1.21 (0.56–2.64)

0.630

 Sensitivity analysis 1

  

169.1

48.2

0.78 (0.47–1.27)

0.318

 Sensitivity analysis 2

  

98.9

49.5

0.82 (0.47–1.43)

0.483

  1. Axi-cel, axicabtagene ciloleucel; CI, confidence interval; CRR, complete response rate; ESS, effective sample size; liso-cel, lisocabtagene maraleucel; N, sample size; OR, odds ratio; ORR, objective response rate